Here, we report the results of a Spanish study that compared the usage patterns of daily G-CSF and pegfilgrastim, and the respective outcomes in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy. This evidence concerns the gene CSF3 and myeloid neoplasm.